Hengrui Medicine: Subsidiary HRS9531 Injection Receives Clinical Trial Approval.

Hengrui Pharmaceuticals announced that its subsidiary Fujian Shengdi Pharmaceuticals Co., Ltd. has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for HRS9531 injection. The indication for the application is to reduce the risk of major cardiovascular events in patients with atherosclerotic cardiovascular disease. HRS9531 injection, with HRS9531 as the main active ingredient, is a new type of dual agonist targeting the gastrin receptor and glucagon-like peptide-1 receptor with global proprietary intellectual property. It can regulate glucose and lipid metabolism, suppress appetite, and enhance insulin sensitivity in the body, thereby improving blood sugar levels and reducing weight.